Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 2/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.54 |
| ▸ | CALCRL | Q16602 | 3/20 | 0.52 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.52 |
| ▸ | CALCR | P30988 | 4/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14549924 | 1.00 | KEAP1 (0.56) | KEAP1SLC6A2OPRM1OPRD1CALCRL | |
| SCHEMBL30163250 | 1.00 | KEAP1 (0.56) | KEAP1SLC6A2OPRM1OPRD1CALCRL | |
| SCHEMBL15130591 | 0.97 | OPRM1 (0.55) | KEAP1SLC6A2OPRM1OPRD1CALCR | |
| SCHEMBL28210612 | 0.97 | OPRM1 (0.55) | KEAP1SLC6A2OPRM1OPRD1CALCR | |
| SCHEMBL30163263 | 0.97 | OPRM1 (0.55) | KEAP1SLC6A2OPRM1OPRD1CALCR | |
| SCHEMBL14549930 | 0.97 | OPRM1 (0.55) | KEAP1SLC6A2OPRM1OPRD1CALCR | |
| SCHEMBL28846618 | 0.97 | OPRM1 (0.55) | KEAP1SLC6A2OPRM1OPRD1CALCR | |
| SCHEMBL30163405 | 0.96 | OPRM1 (0.56) | KEAP1SLC6A2OPRM1OPRD1CALCR | |
| SCHEMBL30163248 | 0.95 | OPRM1 (0.55) | KEAP1SLC6A2OPRM1OPRD1CALCR | |
| SCHEMBL29597272 | 0.94 | OPRM1 (0.55) | KEAP1SLC6A2OPRM1OPRD1CALCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170157200-A1 | Low-Dose Stable Formulations of Linaclotide | IRONWOOD PHARMACEUTICALS INC (US) | 2017-06-08 | — | — | US | disclosed |
| US-20160310559-A1 | Delayed Release Compositions of Linaclotide | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2016-10-27 | — | — | US | disclosed |
| US-8802628-B2 | Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administration | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-20130273169-A1 | Stable Solid Formulation of GC-C Receptor Agonist Polypeptide Suitable for Oral Administration | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2013-10-17 | — | — | US | disclosed |
| US-20130190239-A1 | Formulations Comprising Linaclotide | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2013-07-25 | — | — | US | disclosed |
| US-8293704-B2 | Crystalline form of linaclotide | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (IE) | 2012-10-23 | — | — | US | disclosed |
| US-20120214750-A1 | CRYSTALLINE FORM OF LINACLOTIDE | FOREST LABORATORIES HOLDINGS LTD. (BM) | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214750-A1 | CRYSTALLINE FORM OF LINACLOTIDE | LPXN, LIPA, PDE6C | KEAP1 2781/4885SLC6A2 2881/4885OPRM1 2547/4885 |
| US-20160310559-A1 | Delayed Release Compositions of Linaclotide | LPXN, LHCGR, BRS3 | KEAP1 3315/4885SLC6A2 557/4885OPRM1 1073/4885 |
| US-20170157200-A1 | Low-Dose Stable Formulations of Linaclotide | LPXN, PDE8A, PDE8B | KEAP1 2442/4885SLC6A2 1641/4885OPRM1 1183/4885 |
| US-20130190239-A1 | Formulations Comprising Linaclotide | LPXN, LPAR3, LPAR5 | KEAP1 2514/4885SLC6A2 1856/4885OPRM1 1058/4885 |
| US-20130273169-A1 | Stable Solid Formulation of GC-C Receptor Agonist Polypeptide Suitable for Oral Administration | GCGR, GLP1R, GCG | KEAP1 4126/4885SLC6A2 988/4885OPRM1 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.